The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are ...

Pfizer claims Metsera breached their merger agreement, adding that a tie-up of the biotech with GLP-1 drug giant Novo Nordisk ...

With federal PBM reform stalled, states like California are stepping up with laws like SB 41 to boost transparency and lower ...

More than 60 healthcare startups have been built at Redesign Health since it was founded in 2018. This week, the company closed a $175 million investment for a new fund to fuel the creation of even ...

The prosthetics field’s main problem isn’t just designing better devices — it’s the lack of data to guide which device is best for each patient, according to one executive in the space. Josh Caputo, ...

More than 30 birth control products have cost-sharing requirements or coverage exclusions, a violation of the Affordable Care Act, according to an investigation by the House Committee on Oversight and ...

The Food and Drug Administration will remove black box warnings from hormone replacement therapy (HRT) products, which are often used to treat menopause, the Department of Health and Human Services ...

The six new drugs awarded FDA Commissioner’s National Priority Vouchers brings to 15 the total number of therapies selected for the new pilot program. Under this program, the FDA says the standard 10- ...

Hair loss is not an unserved market, but it’s not a well-served one. The available drugs are older products initially developed for other indications and they don’t address hair loss’s underlying ...

Each year, the HLTH conference gives healthcare leaders a chance to gather and share ideas. The event also gives companies the chance to announce news — oftentimes about new products, partnerships and ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The ...